## Michele Ceribelli

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10661805/publications.pdf

Version: 2024-02-01

24 papers

3,500 citations

279798 23 h-index 610901 24 g-index

26 all docs

26 docs citations

times ranked

26

6470 citing authors

#	Article	IF	CITATIONS
1	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature, 2012, 490, 116-120.	27.8	759
2	Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 21, 723-737.	16.8	460
3	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell, 2017, 31, 833-843.e5.	16.8	383
4	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature, 2018, 560, 387-391.	27.8	276
5	Oncogenic Mechanisms in Burkitt Lymphoma. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014282-a014282.	6.2	187
6	Blockade of oncogenic $\hat{\mathbb{I}}$ kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11365-11370.	7.1	166
7	Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. Cancer Discovery, 2014, 4, 480-493.	9.4	130
8	Malignant pirates of the immune system. Nature Immunology, 2011, 12, 933-940.	14.5	120
9	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Cell, 2016, 30, 764-778.	16.8	116
10	The Histone-Like NF-Y Is a Bifunctional Transcription Factor. Molecular and Cellular Biology, 2008, 28, 2047-2058.	2.3	107
11	Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells. Journal of Experimental Medicine, 2013, 210, 2151-2159.	8.5	102
12	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. Cancer Cell, 2016, 29, 494-507.	16.8	93
13	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. Cancer Cell, 2018, 34, 286-297.e10.	16.8	88
14	Isoform-Specific Expression and Feedback Regulation of E Protein TCF4 Control Dendritic Cell Lineage Specification. Immunity, 2017, 46, 65-77.	14.3	84
15	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 2021, 54, 116-131.e10.	14.3	72
16	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7260-E7267.	7.1	53
17	ETO family protein Mtg16 regulates the balance of dendritic cell subsets by repressing Id2. Journal of Experimental Medicine, 2014, 211, 1623-1635.	8.5	49
18	Repression of New p53 Targets Revealed by ChIP on Chip Experiments. Cell Cycle, 2006, 5, 1102-1110.	2.6	47

#	Article	IF	CITATION
19	Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells. Immunity, 2015, 43, 277-288.	14.3	47
20	Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clinical Cancer Research, 2017, 23, 7301-7311.	7.0	44
21	NF-YC Complexity Is Generated by Dual Promoters and Alternative Splicing. Journal of Biological Chemistry, 2009, 284, 34189-34200.	3.4	31
22	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. Blood Cancer Discovery, 2021, 2, 630-647.	5.0	30
23	An NF-Y-Dependent Switch of Positive and Negative Histone Methyl Marks on CCAAT Promoters. PLoS ONE, 2008, 3, e2066.	2.5	28
24	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood, 2022, 139, 538-553.	1.4	27